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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by a gradual decline in memory associated
with shrinkage of brain tissue, with localized loss of neurons mainly in the hippocampus and basal forebrain, with diminished
level of central cholinergic neurotransmitter-acetylcholine and also reported to be associated with accumulation of ubiquitinated
proteins in neuronal inclusions and also with signs of inﬂammation. In these disorders, the abnormal protein aggregates may
themselves trigger the expression of inﬂammatory mediators, such as cyclooxygenase 2 (COX-2). In the present study, the eﬀects
of Meloxicam, Selegiline, and coadministration of these drugs on scopolamine-induced learning and memory impairments in
mice were investigated. Rectangular maze test, Morris water maze test, Locomotor activity, and Pole climbing test were conducted
to evaluate the learning and memory parameters. Various biochemical parameters such as acetylcholinesterase(AChE), TBARS
assay, catalase activity, and DPPH assay were also assessed. The present study demonstrates that Meloxicam, Selegiline, and
co-administration of these test drugs had potential therapeutic eﬀects on improving the antiamnesic activity in mice through
inhibiting lipid peroxidation, augmenting endogenous antioxidant enzymes, and decreasing acetylcholinesterase activity in brain.
The memory enhancing capacity of the drugs was very signiﬁcant when compared to disease control (P<0.001).
1.Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
braindisorderthatisslowinonsetbutleadstodementia,un-
usual behavior, personality changes, and ultimately death
[1]. AD is characterized by the presence of excessive amounts
of neuritic plaques containing amyloid β protein and ab-
normal tau protein ﬁlaments in the form of neuroﬁbrillary
tangles. Loss of cholinergic cells, particularly in the basal
forebrain, is accompanied by loss of the neurotransmitter
acetylcholine [2]. A decrease in acetyl choline in the brain
of patients with AD appears to be a critical element in pro-
ducing dementia [3]. AChE inhibitors from general chemical
classes such as physostigmine, tacrine, galantamine, and
heptylphysostigmine have been tested for the symptomatic
treatment of AD [4]. However, nonselectivity of these drugs,
theirlimitedeﬃcacy,poorbioavailability,adversecholinergic
side eﬀects in the periphery, narrow therapeutic ranges, and
hepatotoxicityareamongtheseverallimitationstotheirther-
apeutic success [5]. Therefore, it is worthwhile to explore the
utility of other existing medicines for the treatment of var-
ious cognitive disorders [6].
Scopolamine, a muscarinic cholinergic receptor antago-
nist, has been widely adopted to study cognitive deﬁcits in
experimentalanimals.Afterintraperitoneal(i.p.)injectionof
scopolamine, the cholinergic neurotransmission was block-
aded, leading to cholinergic dysfunction and impaired co-
gnition in rats [7] .R e c e n t l y ,i th a sb e e nr e p o r t e dt h a tm e m -
ory impairment induced by scopolamine in rats is associated
with altered brain oxidative stress status [8]. Therefore, rats
with scopolamine-induced memory deﬁcits were used as an
animal model for screening antidementia drugs [9].
Oxidative stress is also one of the aﬀecting factors in AD,
soseveralantioxidantshavebeenstudiedforthereductionof
oxidative stress occurring during Alzheimer’s disease [10,
11]. One of the mechanisms by which the abnormal2 International Journal of Alzheimer’s Disease
Table 1
Group-I Control Vehicle (0.1% CMC).
Group-II Disease control Scopolamine (1.4mg/kg) i.p.
Group-III Standard Donepezil (5mg/kg) oral + Scopolamine (1.4mg/kg) i.p.
Group-IV Test-I Meloxicam (5.2mg/kg) oral + Scopolamine (1.4mg/kg) i.p.
Group-V Test-II Selegiline (0.49mg/kg) p.o. + Scopolamine (1.4mg/kg) i.p.
Group-VI Test-III Meloxicam (5.2mg/kg) oral + Selegiline (0.49mg/kg) oral + Scopolamine (1.4mg/kg) i.p.
accumulation of ubiquitinated proteins may mediate neu-
rodegeneration is by triggering an inﬂammatory response.
In-ﬂammation is a defense reaction against diverse insults,
intended to remove damaging agents and to inhibit their
detrimental eﬀects [12]. Those agents were found to increase
neuronal levels of cyclooxygenase 2 (COX-2) suggesting that
the production of such inﬂammatory mediators can be trig-
geredbytheintracellularaccumulationofabnormalproteins
[13]. Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
the group of drugs which eﬀectively interfere with the cyclo-
oxygenase pathway which is involved in generation of oxi-
dative free radicals. In rheumatoid arthritis, NSAIDs have
showedimprovementinthecirculatingantioxidantstatuson
daily dosing treatment [14, 15].
For that purpose, meloxicam (an enolic derived NSAID)
has been taken as reference drug by basing on the possession
of signiﬁcant anti-inﬂammatory activity as well as antiox-
idant property [16]. It has preferential inhibitory activity
againsttheinduciblecyclooxygenase-2isoform,overthecon-
stitutive isoform cyclooxygenase-1. Therefore, meloxicam
and other COX-2 selective inhibitors are promoted for their
safer proﬁle of side eﬀects.
Selegiline (L-deprenyl), an irreversible inhibitor of mon-
oamine oxidase-B (MAO-B), a therapeutic agent of Parkin-
son’s disease, is known to have neuroprotective properties
that may involve its regulatory eﬀects on antioxidant enzy-
mes. In addition, selegiline may act as an antioxidant in neu-
rons and protect against glutamate-receptor-mediated tox-
icity. Studies of selegiline on aged male laboratory animals
have showed delayed cognitive impairment and behavioral
deterioration when compared with control animals [17].
The main purpose of the present study was to investigate
the synergistic action of meloxicam and selegiline in scop-
olamine-induced Alzheimer’s disease model.
2.MaterialsandMethods
2.1. Animals. Swiss mice of male sex weighing 20–25g were
used in the present study. They had free access to food and
water and were maintained under standard laboratory con-
ditions with alternating light and dark cycles of 12h each.
They were acclimatized to laboratory conditions for 2 days
before behavioral studies. All the readings were taken during
the same time of the day, that is, between 10 am and 2 pm.
The Institution Animals Ethics Committee (IAEC) had ap-
proved the experimental protocol, and care of animals was
taken as per guidelines of CPCSEA, Department of Animal
Welfare, and Government of India [18].
2.2. Drugs. Scopolamine (Cadila Healthcare pvt. Ltd), Sel-
egiline(INTASpharmaceuticals),andDonepezil(Alkemlab-
oratories Ltd.) were purchased. Meloxicam was gifted by Dr.
Reddy’s Labarotaries. Scopolamine and selegiline were dil-
uted with distilled water.
2.3. Experimental Design. The animals (n = 36) were divid-
ed into six diﬀerent groups of 6 animals per each group.
Scopolamine (1.4mg/kg) as a disease inducer was adminis-
tered to all groups through intraperitoneal (i.p) route after
drugs administration to all the groups except normal control
group. The same procedure was carried out for 9 days (see
Table 1).
2.4.BehaviouralTests. Alltheanimalsweretrainedfor2days
before drugs administration.
2.4.1. Rectangular Maze Test. Assessment of learning and
memory can be eﬀectively done by this method. The maze
consistsofcompletelyenclosedrectangularboxwithanentry
and reward chamber appended at opposite ends. The box is
partitionedwithwoodenslatsintoblindpassagesleavingjust
twisting corridor leading from the entry to the reward cham-
ber. Animals were trained prior to the experiment by fam-
iliarizing with the rectangular maze for a period of 10min
for 2h. Well-trained animals were taken for the experiment.
Transfer latency (time taken to reach the reward chamber)
was recorded. For each animal, four readings were taken and
the average is taken as learning score (transfer latency) for
that animal. Lower scores of assessment indicate eﬃcient
learning while higher scores indicate poor learning in an-
imals. The time taken by the animals to reach the reward
chamber from the entry chamber was noted on day 1, 3, 5,
7, and 9 [19].
2.4.2. Morris Water Maze Test. Morris water maze was used
to assess learning and memory in experimental mice. There
are several advantages of Morris water maze over other mod-
els of learning and memory including absence of motiva-
tional stimuli such as food and water deprivation, electrical
stimulations, and buzzer sounds [20, 21]. Brieﬂy, it consistsInternational Journal of Alzheimer’s Disease 3
of a circular water tank, ﬁlled with opaque water, and one
centimeter submerged platform. First, animals were trained
to locate the platform. During acquisition, trial escape late-
ncy time (ELT), time measure to locate the hidden platform,
was noted as an index of acquisition. Each animal was sub-
jected to the four acquisition trials per day for 4 consecutive
days. The time spent by the animal, searching for the mis-
sing platform in target quadrant Q2 with respect to other
quadrant(Q1,Q3,andQ4)on5thday,wasnotedasanindex
ofretrieval.Forstudyingtheeﬀectofdrugonacquisition,the
drug solution was administered before acquisition trial [22].
2.4.3. Locomotor Activity. Locomotor activity is inﬂuenced
by most of the CNS drugs in both man and animals. The lo-
comotor activity of drug can be studied using actophotome-
ter which operates on photoelectric cells which are con-
nected in circuit with a counter when the beam of light fal-
l i n go np h o t o c e l li sc u to ﬀ by the animal, then a count is
recorded. Animals are placed individually in the activity cage
for 10min and the activity was monitored. The test is done
before 30min and after the drug administration. The photo
cell count is noted and decrease or increase in locomotor
activity is calculated [20].
2.4.4. Pole Climbing Test. When an electrical stimulus is
given to animal, it tries to escape from it and move to the
near safe place. This equipment is designed in such a way to
climb the pole when stimulus is generated. Prior to the
experiment, animals were trained. Training and testing is
conducted in a 25 × 25 × 40cm chamber that is enclosed
in a dimly light, sound attenuated box. Scrambled shock is
delivered to the grid ﬂoor of the chamber. A smooth stainless
steel pole, 2.5cm in diameter, is suspended by a counter
balance weight through a hole in the upper centre of the
chamber. A micro switch is activated when the pole is pulled
downby3mm.Withweightgreaterthan200gm.Aresponse
is recorded when a mice jumps on the pole and activates mi-
cro switch. The activation of light and speaker together is
used as conditioned stimulus. Each animal was placed six
times per day [20].
2.5. Histopathological Studies. After 8-day treatment, the
brains of diﬀerent groups were perfusion-ﬁxed with 4% pa-
raformaldehyde in 0.1M phosphate buﬀer. The brains were
removedandpostﬁxedinthesameﬁxativeovernightat48◦C.
The brains were then routinely embedded in paraﬃna n d
stained with Hematoxylin-Eosin. The hippocampal lesions
were assessed microscopically at 40 magniﬁcation [23].
2.6. Dissection and Homogenization. On day 9, after behav-
ioral assessments, animals were scariﬁed by cervical dislo-
cation. The brains were removed. Each brain was separately
put on ice and rinsed with ice-cold isotonic saline. A (10%
w/v) homogenate was prepared in 0.1M phosphate buﬀer
(pH 7.4). The homogenate was centrifuged at 3000rpm for
15 minutes and aliquots of supernatant were separated and
used for biochemical estimation [23].
2.7. Biochemical Tests
2.7.1. AchE Estimation. The cholinergic marker, acetylchol-
inesterase, was estimated in the whole brain according to the
method of Ellman method. Ellman’s reagent is 5, 5 -dith-
iobis(2-nitrobenzoate) and it is also abbreviated as DTNB.
This homogenate was incubated for 5min with 2.7mL of
phosphate buﬀer and 0.1mL of DTNB. Then, 0.1mL of
freshly prepared acetylthiocholine iodide (pH 8) was added
and the absorbance was read at 412nm [24, 25].
2.7.2.ThiobarbituricAcidReactiveSubstances(TBARS)Assay.
This assay is used to determine the lipid peroxidation. Aliq-
uots of 0.5mL distilled water were added with1 mL of 10%
trichloroacetic acid and were added with 0.5mL of brain
tissue homogenate. This is centrifuged at 3000rpm for
10min. To the 0.2mL supernatant, 0.1mL thiobarbituric
acid (0.375%) was added. Total solution is placed in water
bath at 80◦c for 40min and cooled at room temperature.
Absorbance was read at 532nm [26].
2.7.3. Catalase Activity. Catalase activity was assessed by the
method of Luck [27], wherein the breakdown of hydrogen
peroxide is measured. In this 3mL of H2O2 phosphate buf-
fer was added to 0.05mL of the supernatant of the tissue ho-
mogenate. The absorbance was recorded at 240nm using
Perkin Elmer Lambda 20 spectrophotometer. The results
were expressed as micromoles of H2O2decomposed per min-
ute per mg protein [25].
2.7.4. DPPH (2,2-Diphenyl-1-picrylhydrazyl) Assay. In this,
measurement is made from the bleaching of purple-coloured
methanol solution of DPPH. To the 1000μL of diverse conc.
of the sample, 4mL of 0.004% methanolic solution of DPPH
was added. After 30min incubation, absorbance was read at
517nm. Inhibition of free radical by DPPH in % was cal-
culated in the following way:
% =

Ablank −Asample/Ablank

×100, (1)
Ablank: absorbance of control reaction. Asample: absorb-
ance of test sample. Values of inhibition were calculated [26].
2.8. Statistical Analysis. The statistical analysis of data was
done by the one way analysis of variance (ANOVA) followed
by the Dunnett’s test. The probability level less than 0.05 was
considered as signiﬁcant. Results were expressed as mean ±
SD.
3. Results
3.1. Behavioural Tests
3.1.1. Rectangular Maze Test. The activity of meloxicam and
selegiline was evaluated using rectangular maze. The mice
in all treatment groups except scopolamine-treated group
showed lower transfer latency on 7th day and 9th day4 International Journal of Alzheimer’s Disease
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Figure 1: Rectangular maze test. Eﬀect of meloxicam and selegiline
on latency time compared to the disease control group. (Mean ±
SD, n = 6). Graph showing mean ± SD of latency time in seconds.
aP<0.001, bP<0.01, cP<0.05 compared with corresponding
values of disease control.
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Figure 2:Morriswatermazetest.Eﬀectofmeloxicamandselegiline
on latency time compared to the disease control group. (Mean ±
SD, n = 6). Graph showing mean ± SD of latency time in seconds.
aP<0.001, bP<0.01, cP<0.05 compared with corresponding
values of disease control.
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Figure 3: Locomotor activity. Eﬀect of meloxicam and selegiline
on latency time compared to the disease control group. (Mean ±
SD, n = 6). Graph showing mean ± SD of latency time in seconds.
aP<0.001, bP<0.01, cP<0.05 compared with corresponding
values of disease control.
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Figure 4: Pole climbing test: Eﬀect of meloxicam and selegiline on
latency time levels compared to the disease control group (Mean ±
SD, n = 6). Graph showing mean ± SD of latency time in seconds.
aP<0.001, bP<0.01, cP<0.05 compared with corresponding
values of disease control.
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Figure 5: AchE estimation. Eﬀect of meloxicam and selegiline on
AchE levels compared to the disease control group. (Mean ± SD,
n = 6).Graphshowingmean ±SDof%inhibitionofAchEenzyme.
aP<0.001 compared with corresponding values of disease control.
compared to 5th day of the same group as well as with
the scopolamine group which was given in Figure 1. This in
dicates memory enhancing capacity of the meloxicam and
selegiline. Donepezil (5mg/kg) treated for successive 8 days
acts as positive control, possessed signiﬁcant (P<0.05) de-
crease in transfer latency when compared to normal control
and disease control (scopolamine) using Dunnet’s test.International Journal of Alzheimer’s Disease 5
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Figure 6: TBARS assay. Eﬀect of meloxicam and selegiline on mal-
ondialdehyde levels compared to the disease control group. (Mean
± SD, n = 6). Graph showing mean ± SD of malondialdehyde
levels. aP<0.001 compared with corresponding values of disease
control.
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Figure 7: Catalase activity. Eﬀect of meloxicam and selegiline on
catalase activity compared to the disease control group. (Mean ±
SD, n = 6). Graph showing mean ± SD of %H2O2 scavenging
activity. aP<0.001 compared with corresponding values of disease
control.
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Figure 8: DPPH assay. Eﬀect of meloxicam and selegiline on
inhibition of DPPH compared to the disease control group (Mean
± SD, n = 6). Graph showing mean ± SD of % inhibition of DPPH.
P<0.001 compared with corresponding values of disease control.
3.1.2.MorrisWaterMazeTest. Theactivityofmeloxicamand
selegiline wAS evaluated using Morris water maze. The mice
treatment groups except scopolamine-treated group showed
signiﬁcant transfer latency on 4th day with platform and
on 5th day without platform which was given in Figure 2.
This indicates memory enhancing capacity of the meloxicam
and selegiline. Donepezil (5mg/kg) treated for successive
8 days acts as positive control, possessed signiﬁcant (P<
0.05) decrease in transfer latency when compared to disease
control (scopolamine) using dunnet’s test.
3.1.3. Locomotor Activity. The activity of meloxicam and
selegiline was evaluated using photoactometer. The mice
showed signiﬁcant transfer latency on 7th day compared to
the 9th day in all treatment groups except scopolamine-
treated group which was given in Figure 3.T h i sD o n e p e z i l
( 5m g / k g )t r e a t e ds u c c e s s i v e8d a y sa c t sa sp o s i t i v ec o n t r o l ,
possessed signiﬁcant (P<0.05) decrease in number of cros-
sings which is comparable to the other treatment groups.
3.1.4. Pole Climbing Test. The values show that there was a
signiﬁcant diﬀerence that has been observed on days 7 and
9 compared to the 1, 3, and 5. Scopolamine-treated group
took more time whereas the control and drug-treated groups
showed less time to reach the pole in pole climbing appara-
tus. The results showed that synergistic action of meloxicam
and selegiline was signiﬁcant (P<0.05) and is comparable
to the standard drug (donepezil).6 International Journal of Alzheimer’s Disease
Histopathological studies:
(a) (b)
(c) (d)
(e) (f)
Figure 9:Histopathological studies.TheseFigures (a),(b),(c),(d),(e),and(f)arenormalcontrol, scopolamine (diseasecontrol),donepezil
(standard), meloxicam, selegiline, and meloxicam + selegiline, respectively, representing the histological sections of the brain tissue showing
neurological lesions.
3.2. Biochemical Tests
3.2.1. AchE Estimation. Scopolamine treatment signiﬁcantly
increased the brain AchE level compared to control group
(Figure 5). Standard drug (donepezil) and test drugs (mel-
oxicam,selegiline)treatmentsigniﬁcantlyinhibitedthebrain
AchE level compared to their corresponding scopolamine-
treated groups.
3.2.2. TBARS Assay. Scopolamine treatment signiﬁcantly in-
creased the brain MDA level compared to control group
(Figure 6). Standard drug (donepezil) and test drugsInternational Journal of Alzheimer’s Disease 7
(meloxicam,selegiline) treatment signiﬁcantly (P<0.05) de-
creased brain MDA level compared to their corresponding
scopolamine treated groups.
3.2.3.CatalaseActivity. Catalaselevelsweredecreasedinsco-
polamine-treated groups compared to the normal control
group (Figure 7). Signiﬁcant (P<0.05) diﬀerence has been
foundindrug-treatedgroups.Synergisticeﬀectwasobserved
whichiscomparablewiththestandardgroupthanindividual
drug-treated groups.
3.2.4. DPPH Assay. Antioxidant levels were decreased in
scopolamine-treated group compared to the control group
(Figure 8). Drug-treated groups showed signiﬁcant (P<
0.05) diﬀerence compared to the disease control group.
3.3. Histopathological Studies. From Figure 9,i ti sc l e a r l y
visible that in disease control group the degenerated cells are
more compared to other groups. This will be indicated by
thegapsinslides.Thedrug-treatedgroupsareinbetweenthe
normalcontrolanddiseasecontrolgroups.Thecombination
group is mostly near to the control group compared to the
individual drug-treated groups.
4. Discussion
The scopolamine amnesia test is widely used as primary
screening test for so-called anti-Alzheimer drugs [24].
There recently has been an increased appreciation of
the role that inﬂammation plays in the pathogenesis of
Alzheimer’s disease that has arisen principally from epi-
demiological studies showing a dramatic eﬀect of long-term
NSAID treatment on Alzheimer’s disease risk. However, the
molecuar mechanisms by which NSAIDs intervene in the
pathological processes that underlie cognitive decline and
neuronal loss remain unclear [28, 29].
Recently, many studies reported that memory impair-
mentinthescopolamine-inducedanimalmodelisassociated
with increased oxidative stress within the brain [8, 30, 31].
Oxidative stress is the cytotoxic consequence of oxyradical
and oxidant formation and the reaction with cellular con-
stituents.Reactiveoxidativespecies(ROS)aregeneratedcon-
tinuously in nervous system during normal metabolism and
neuronal activity. The nervous system is particularly vulner-
able to the deleterious eﬀects of ROS. Because the brain has
a high consumption of oxygen, large amount of polyunsatu-
rated fatty acids (PUFAs), high contents of free ions, and low
levels of antioxidants defense were compared to other organs
[32]. Increased MDA level as one of the ROS has been shown
to be an important marker for in vivo lipid peroxidation.
From the behavioral test, that is, rectangular maze test
and Morris water maze test, it is clearly seen that there was a
general decrease in the transfer latency in all treated groups
compared to the scopolamine-treated group. The memory
loss eﬀect of scopolamine is more prominent compared to
the control group. In comparison with Donepezil, the drug-
treated groups had almost equal performance which indi-
cates synergistic eﬀect of meloxicam and selegiline against
memory loss. Meanwhile locomotor activity and pole climb-
ing avoidance tests are done which also indicate the leaning
ability (Figure 4).
The major antioxidant and oxidative free radical scav-
enging enzymes like glutathione, SOD, and catalase play an
important role to reduce oxidative stress in brain. In this
study, from the DPPH assay antioxidant levels are estimated.
These enzyme levels are decreased in the scopolamine-treat-
ed group compared to the control group. The enzyme levels
are almost equal in combination group and the stand-
ard group. Individual groups are showing less than standard
group. It supports the antioxidant action of drugs.
In the present study rats after scopolamine treatment
showed a signiﬁcant increase in the brain levels of malondi-
aldehyde, which is the measure of lipid peroxidation and free
radical generation. In the drug-treated groups, there is a sig-
niﬁcant decrease in the levels of malondialdehyde which is
nearly equal to the standard group. From the results, it is
clear that the anti-inﬂammatory activity of meloxicam de-
creases the disease progression. The antioxidant activity of
selegiline is clear from the biochemical tests, which includes
the estimation of antioxidant enzymes.
5. Conclusion
In conclusion, the present study demonstrates that Meloxi-
cam, Selegiline, and co-administration of these test drugs
had potential therapeutic eﬀects on improving the antiam-
nesic activity in mice through inhibiting lipid peroxidation,
augmenting endogenous antioxidant enzymes, and decreas-
ing acetylcholinesterase (AChE) activity in brain.
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